Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage

Area of Science:

• Neonatal Neurology
• Pediatric Critical Care
• Pharmacological Neuroprotection

Background:

• Intraventricular hemorrhage (IVH) is a frequent and severe complication in preterm infants, often leading to poor neurodevelopmental outcomes.
• Current treatments for IVH in neonates are limited, highlighting the need for effective therapeutic strategies.
• Erythropoietin (EPO) has demonstrated neuroprotective properties in preclinical models of neonatal brain injury.

Purpose of the Study:

• To investigate the efficacy of repeated low-dose recombinant human erythropoietin (rhEPO) administration in mitigating adverse outcomes associated with IVH in preterm infants.
• To evaluate the impact of rhEPO on neurodevelopmental trajectories at 18 months corrected age.

Main Methods:

• A single-blinded, prospective, randomized controlled trial was conducted involving preterm infants (gestational age ≤ 32 weeks) diagnosed with IVH within 72 hours of birth.
• Participants were randomized to receive either rhEPO (500 IU/kg) or a placebo (saline) every other day for two weeks.
• The primary endpoint was a composite of death or neurological disability assessed at 18 months of corrected age.

Main Results:

• A total of 316 infants were analyzed (157 rhEPO, 159 placebo).
• While no significant differences were observed in individual mortality or neurological disability rates, the combined incidence of poor outcomes (death and/or neurological disability) was significantly lower in the rhEPO group (14.9% vs. 26.4%, OR 0.398, p=0.009).
• The incidence of severe cognitive impairment (Mental Development Index < 70) was also significantly reduced in infants treated with rhEPO (7.2% vs. 15.3%, OR 0.326, p=0.026).

Conclusions:

• Repeated low-dose rhEPO administration demonstrates a significant benefit in improving overall outcomes for preterm infants suffering from intraventricular hemorrhage.
• This therapeutic approach may offer a novel strategy to enhance neuroprotection and reduce long-term neurodevelopmental deficits in this vulnerable population.